In order to tailor the site to your needs, please click the button that relates best to you.
So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.
Close this windowThis post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
As of 11 August 2022, there are 70 cases (confirmed and probable) of Monkeypox (MPX) in Australia.
New resources available to support the MPX vaccine rollout include:
GPs should identify patients in key risk groups and refer them for vaccination against MPX. Referral pathways for MPX vaccine include:
For more information visit Monkeypox (MPX) vaccines or contact NICMonkeypox@Health.gov.au.
The Pneumosmart Vaccination Tool has been developed to assist GPs, medical specialists and other immunisation providers to comply with the pneumococcal disease vaccination recommendations in the online Australian Immunisation Handbook.
The Pneumosmart tool provides recommendations for different risk conditions and if the condition meets eligibility for NIP funding for pneumococcal vaccine.
From 5 September 2022, COVID-19 vaccines will become available for at-risk children aged 6 months to under 5 years who are most at risk of severe disease. Bookings for Moderna 6 months to under 5 years (Blue/Purple) vaccine will be made available on the Vaccine Clinic Finder website.
All sites who applied in the Expression of Interest (EOI) process have now been notified of the outcome. If you have not received a notification, please email coronavirus@cesphn.com.au. Due to the small population size of the at-risk cohort, not all interested parties were selected, however there may be future opportunities for sites to participate in later stages of the rollout.
On 15 August 2022, new labels were introduced for Pfizer and Moderna COVID-19 vaccines. The new labels will include a thaw “USE BY” date to address the recent increase in vaccine administration errors (VAEs).
The earliest of the thaw use-by date and the batch (manufacturer) expiry is considered as the “USE BY” date. This should include all TGA approved shelf-life extensions.
This information pack includes the latest COVID-19 vaccine information for multicultural communities, translated in up to 63 languages. Translated information in this edition includes:
This fact sheet outlines information on how to access COVID-19 oral treatments for people without a Medicare card and potential costs.
This information video, available in other languages, explains that new, lifesaving oral antiviral treatments are now available for people at high risk of becoming very sick from COVID-19. This social GIF animation, available in other languages, explains who is eligible for COVID-19 oral treatments.
COVID-19 response update
NCIRS webinar: Emerging vaccine preventable diseases and vaccination for travel
See latest Immunisation information – updated weekly
See latest Monkeypox information – updated daily.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. Randwick scientist and grandmother Hilda Stender shared this: What exercise did you do yesterday? I’ve had two knee replacements – one four years ago and the other six months ago. As a result,…
